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Abstract Adenylosuccinate lyase ADSL) deficiency is a de-
fect of purine metabolism affecting purinosome assembly and
reducing metabolite fluxes through purine de novo synthesis
and purine nucleotide recycling pathways. Biochemically this
defect manifests by the presence in the biologic fluids of two
dephosphoryla ted subs t ra tes of ADSL enzyme:
succinylaminoimidazole carboxamide riboside (SAICAr)
and succinyladenosine (S-Ado). More than 80 individuals
with ADSL deficiency have been identified, but incidence of
the disease remains unknown. The disorder shows a wide
spectrum of symptoms from slowly to rapidly progressing
forms. The fatal neonatal form has onset from birth and
presents with fatal neonatal encephalopathy with a lack of
spontaneous movement, respiratory failure, and intractable
seizures resulting in early death within the first weeks of life.
Patients with type I (severe form) present with a purely neu-
rologic clinical picture characterized by severe psychomotor
retardation, microcephaly, early onset of seizures, and autistic
features. A more slowly progressing form has also been
described (type II, moderate or mild form), as having later
onset, usually within the first years of life, slight to moderate
psychomotor retardation and transient contact disturbances.
Diagnosis is facilitated by demonstration of SAICAr and S-
Ado in extracellular fluids such as plasma, cerebrospinal fluid
and/or followed by genomic and/or cDNA sequencing and
characterization of mutant proteins. Over 50 ADSL mutations
have been identified and their effects on protein biogenesis,
structural stability and activity as well as on purinosome
assembly were characterized. To date there is no specific and
effective therapy for ADSL deficiency.
Abbreviations
ADSL adenylosuccinate lyase deficiency
AICAR aminoimidazole carboxamide ribotide
CSF cerebrospinal fluid
HPLC high-pressure liquid chromatography
MRI magnetic resonance imaging
MS/MS tandem mass spectrometry
PP purine and pyrimidine
SAICAR succinylaminoimidazole carboxamide ribotide
SAICAr succinylaminoimidazole carboxamide riboside
S-Ado succinyladenosine
TLC thin layer chromatography
Definition
Adenylosuccinate lyase deficiency (OMIM 103 050) is an
autosomal recessive defect of purine metabolism. It was first
described in 1984 by Jaeken and van den Berghe (Jaeken and
Van den Berghe 1984), who found succinylpurines in the
cerebrospinal fluid (CSF), plasma, and urine of three patients
with severe psychomotor delay and autistic features.
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The enzyme adenylosuccinate lyase (EC 4.3.2.2) catalyzes
two non-sequential steps in the de novo synthesis of purine
nucleotides leading to nonhydrolytic cleavage of succinyl
g r oup s t o y i e l d f uma r a t e : t h e conve r s i on o f
succinylaminoimidazole carboxamide ribotide (SAICAR) in-
to aminoimidazole carboxamide ribotide (AICAR) and the
formation of adenosine monophosphate nucleotides (Fig. 1).
In addition to its role in purine biosynthesis, the enzyme is
involved, together with adenylate deaminase and
adenylosuccinate synthetase, in the purine nucleotide cycle.
This cycle prevents adenosine monophosphate (AMP) accu-
mulation following adenosine triphosphate (ATP) catabolism,
and this, in turn, displaces the adenylate kinase reaction to-
ward adenosine triphosphate formation (Sabina et al 1980).
Moreover, the purine nucleotide cycle plays a role in main-
taining the adenylate energy charge through the generation of
intermediates for the citric-acid cycle from amino acids and
through the stimulation of activities of glycogen phosphory-
lase and of phosphofructokinase, thus enhancing the rate of
glycolysis (Tornheim and Lowenstein 1975; Aragon and
Lowenstein 1980; Young et al 1996).
The native human ADSL protein is a homotetramer with a
subunit size of ~50 kDa. The protein contains four active sites.
Each of them is formed from regions of three different
subunits - Protein Data Bank (PDB) (2VD6; http://www.
pdb.org/pdb/cgi/explore.cgi?pdbId=2VD6).
The enzyme defect (MIM 103050) manifests itself by the
presence in the biologic fluids of two normally undetectable
compounds, succinylaminoimidazole carboxamide riboside
(SAICAr) and succinyladenosine (S-Ado), which are formed
by dephosphorylation of the two substrates of the enzyme.
Epidemiology
Incidence of ADSL deficiency remains unknown. To date
almost 80 patients have been reported and the majority of
them were found in Holland and Belgium, where the defect
was discovered for the first time (Jaeken and Van den Berghe
1984; Kohler et al 1999). Other reported patients were from
Czech Republic (Kmoch et al 2000; Mouchegh et al 2007),
Poland (Jurecka et al 2008a, b), Germany (Kohler et al 1999;
Mouchegh et al 2007), UK (Lundy et al 2010), Spain (Castro
et al 2002; Perez-Duenas et al 2011), Italy (Nassogne et al
2000; Race et al 2000), Portugal (Edery et al 2003), France
(Holder-Espinasse et al 2002), Norway (Marie et al 2002),
Turkey (Kmoch et al 2000; Spiegel et al 2006), Morocco
(Jaeken and Van den Berghe 1984; Stone et al 1992; Gitiaux
Fig. 1 De novo purine biosynthesis pathway. Abbreviations are as follows:
PRPP, phosphoribosylpyrophosphate; SAICAR, succinylaminoimidazole
carboxamide ribotide; SAICAr, succinylaminoimidazole carboxamide
riboside; AICAR, aminoimidazole carbozamide ribotide; FAICAR,
formyloaminoimidazole carboxamide ribotide; IMP, inosine
monophosphate; S-AMP, adenylosuccinate; S-Ado, succinyladenosine;
AMP, adenine monophosphate; XMP, xanthine monophosphate; GMP,
guanine monophosphate; ADSL, adenylosuccinate lyase; AICAR TF,
aminoimidazole carboxamide riboside transformylase; IMP CH, inosine
monophosphate cyclohydrolase; ATIC, bifunctional enzyme AICAR
transformylase/IMP cyclohydrolase
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et al 2009), Malaysia (Chen et al 2010), Australia (Stathis et al
2000; van Werkhoven et al 2013), Colombia (Castro et al
2002), and the US (Kmoch et al 2000; Spiegel et al 2006).
Detailed and regularly updated information on identified pa-




Although there is wide variation in the clinical presentation
observed in patients with ADSL deficiency, descriptive sys-
tems have classified patients’ phenotypes as severe type I
form, milder type II form, and fatal neonatal form (Jurecka
et al 2008a, b).
Fatal neonatal form of ADSL deficiency
Recently, a larger number of patients with a neonatal form
have been reported (van den Bergh et al 1998; Jurkiewicz et al
2007; Mouchegh et al 2007; Jurecka et al 2008a, b; Lundy
et al 2010). These patients presented with fatal neonatal en-
cephalopathy with a lack of spontaneous movement (“floppy
infant”), respiratory failure and intractable seizures resulting
in early death within the first weeks of life. Additionally it has
been reported that ADSL may have prenatal manifestations,
with impaired intrauterine growth, microcephaly, fetal
hypokinesia (with all its consequences, up to arthrogryposis
and pulmonary hypoplasia), and a loss of fetal heart rate
variability (Mouchegh et al 2007).
Type I ADSL deficiency
Most of the patients reported so far have adenylosuccinate
lyase deficiency type I (severe form) with a purely neurologic
clinical picture characterized by severe psychomotor retarda-
tion, early onset of seizures and microcephaly. These patients
present within the first months of life and the further evolution
is characterized by developmental arrest, lack of eye-to-eye
contact and in some patients coma vigil (Jaeken et al 1988;
Krijt et al 1994; Valik et al 1997; Kohler et al 1999; Jurecka
et al 2008a, b; Gitiaux et al 2009; Lundy et al 2010; Jurecka
et al 2012a, b). Severe cortical visual impairment correspond-
ing to the degree of encephalopathy may also be a feature of
the severe phenotype (Lundy et al 2010).
Type II ADSL deficiency
Patients with type II (moderate or mild form), who develop
symptoms within the first years of life, usually suffer from
slight to moderate psychomotor retardation and transient
contact disturbances (Jaeken et al 1988; Jaeken et al 1992;
Jurecka et al 2008a, b; Jurecka et al 2014). Seizures, if present,
appear later, often between the 2nd and 4th year of life (Castro
et al 2002; Jurecka et al 2008a, b), but also reported starting as
late as the 9th year of life (Gitiaux et al 2009). Speech
impairment with a minimal use of words was noticed that
contrast with a higher degree of receptive and non-verbal
communication skills (Gitiaux et al 2009). Another described
problem is ataxia, which may be the cause of increasing gait
disturbance.
The disease manifests symptoms along a continuum and
despite the utility of communicating with the above-mentioned
three descriptive categories; there are no fixed parameters to
ascribe a particular patient to a single category. It has been
suggested that the ratio of the accumulating succinyladenosine
(S-Ado) and succinylaminoimidazolecarboxamide riboside
(SAICAr) in body fluids is not predictive of phenotype severity;
rather, it may be secondary to the degree of the patient’s devel-
opment (i.e., to the age of the patient at the time of a sample
collection) (Zikanova et al 2010).
Clinical manifestations
The majority of ADSL-deficient children are born after un-
complicated pregnancies with normal birth and family history.
The neonatal period in mild form might be normal with
growth parameters in the normal range. In severe type of
disease neurologic symptom might occur early after birth
(Ciardo et al 2001).
Neurological symptoms are the most common and promi-
nent clinical problems associated with adenylosuccinate lyase
deficiency. Particularly common neurologic presentations in-
clude acute encephalopathy, chronic encephalopathy, and be-
havioral abnormalities.
Acute encephalopathy (with seizures)
Acute encephalopathy is the most common presentation in
the neonate and, typically, the affected neonate is born
after a normal pregnancy, at or near term, with a normal
birth weight and remains well in the early hours or days
of life. Such an infant may be discharged from the new-
born nursery, subsequently presenting as acutely unwell.
Early signs of encephalopathy are non-specific, such as
poor feeding, lethargy, vomiting, abnormalities of tone,
and irritability. Later problems may include drowsiness,
fits, hiccups, myoclonus, apneic episodes, marked hypo-
tonia, irritability with cycling movements, seizures, and
coma. Cerebral oedema may develop, contributing to the
relentless deterioration if not treated.
ADSL deficiency can cause onset of epilepsy in the
first year of life. Seizures in early infancy should be
thoroughly investigated for a metabolic basis while other,
J Inherit Metab Dis (2015) 38:231–242 233
more common, causes are investigated. The clinical pic-
ture is usually complex and epilepsy is one of various
other associated neurological symptoms, such as mental
retardation, hypotonia, and microcephaly. Importantly,
convulsions associated with ADSL deficiency may have
a very early onset and be the reason for which the infant
is referred to a neurologist in the first months of life,
despite the presence of other, less easily identified symp-
toms such as delayed psychomotor acquisitions or muscle
tone disorders. General characteristics of seizures second-
ary to ADSL deficiency are as follows: onset in the first
months of life, usually partial; simple partial motor semi-
ology of brief duration; and successive appearance, often
closely related to partial seizures, tonic seizures, spasms,
and massive myoclonus. Resistance to treatment is
common.
Chronic encephalopathy (with or without seizures)
Developmental delay and psychomotor retardation are com-
mon in adenylosuccinase deficiency. There are some charac-
teristics of the cognition which, when present should alert the
clinician to the possibility of an underlying ADSL defect.
First, it tends to be global, affecting all spheres of development
to some extent. Although a mild developmental problem may
present as speech delay, in most cases, a careful history and
developmental examination shows that the defect extends to
other developmental spheres. Secondly, severe irritability,
impulsivity, aggressiveness, and hyperactivity are also com-
mon among infants with mental retardation caused by PP
defects. Thirdly, the psychomotor retardation is usually pro-
gressive. There is generally a history of a period of apparently
normal development, followed by loss of developmental mile-
stones or progressive deterioration in school performance.
Fourthly, the psychomotor retardation is usually associated
with other objective evidence of neurologic dysfunction, such
as disorders of tone (hypotonia sometimes followed after
years by spasticity), seizures, pyramidal tract signs or evi-
dence of extrapyramidal deficits.
Seizures
Corresponding to the clinical diversity, the epileptic pheno-
types associated with ADSL deficiency are also highly vari-
able, comprising myoclonus, partial seizures, infantile
spasms, and status epilepticus (Ciardo et al 2001; Lundy
et al 2010). Seizures usually start either early in the neonatal
period or after the first year of life (van den Bergh et al 1998;
Jurecka et al 2012a, b). Approximately half of the patients
with ADSL deficiency suffer from epilepsy, which is often
intractable, but not always associated with status epilepticus
(Ciardo et al 2001).
Behavioral abnormalities
The autistic features in patients with ADSL deficiency include
failure to make eye-to-eye contact, repetitive behavior, agitation,
temper tantrums, and autoaggressivity (Van den Berghe et al
1997). Several stereotypies might include hand movements,
repetitive manipulation of toys, grimacing, clapping hands, rub-
bing feet, inappropriate laughter, head and trunk rocking, and
stereotyped sounds (Ciardo et al 2001; Perez-Duenas et al 2011).
Gitiaux et al reported behavioral features in two patients, which
combined excessive laughter, a very happy disposition, hyper-
activity, a short/lack attention span, the mouthing of objects,
tantrums, and stereotyped movements (Gitiaux et al 2009).
Dysmorphic features
ADSL deficiency has been reported to have some subtle
dysmorphisms, but the primary and the most obvious problem
is the biochemical derangement. Microcephaly is a character-
istic clinical feature, but is not invariably present in the most
mildly affected patients (Lundy et al 2010). Brachycephaly,
flat occiput, prominent metopic sutures, intermittent divergent
strabismus, small nose with anteverted nostrils, long, smooth
philtrum, and thin upper lip and low set ears have been
reported by Holder-Espinasse (Holder-Espinasse et al 2002).
Other authors described wide mouth, wide-spaced teeth and a
prominent mandible (Gitiaux et al 2009).
Other features
Hypotonia (axial and generalized) is a common feature of
severe type of ADSL deficiency and is often combined with
peripheral hypertonia.
Magnetic resonance imaging studies
Magnetic resonance imaging (MRI) can be a useful tool for
diagnosing and monitoring the pathological progression of the
changes in the course of the disease. Although over 60 pa-
tients with adenylosuccinate lyase deficiency have been re-
ported, there are only 12 reports of brain imaging findings
associated with the condition. These are mostly case reports or
small series of cases with different phenotypes, and correla-
tion with clinical symptoms is ambiguous. Reported findings
on brain MRI in ADSL deficiency include atrophy of the
cerebral cortex, corpus callosum, cerebellar vermis (Van den
Berghe et al 1997; Edery et al 2003; Jurecka et al 2012a, b),
lack of myelination (Kohler et al 1999; Jurecka et al 2012a, b),
delayed myelination (Jurkiewicz et al 2007; Lundy et al 2010;
Jurecka et al 2012a, b), anomalies of the white matter (Valik
et al 1997; Nassogne et al 2000; Edery et al 2003; Marinaki
et al 2004; Lundy et al 2010) and lissencephaly (Stathis et al
2000) (Figs. 2, 3 and 4).
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Etiopathogenesis
Adenylosuccinate lyase deficiency is inherited as an autoso-
mal recessive trait. In humans the ADSL gene spans approx-
imately 23 kb on chromosome 22 (22q13.1q13.2) (Van
Keuren et al 1987; Fon et al 1993). It consists of 13 exons
and its promoter has typical features of house-keeping gene.
The ADSL gene is transcribed in most of the tissues into two
transcript variants which are produced by alternative splicing
of exon 12. Full length variant encodes an active ADSL
protein composed of 484 amino acids. The alternatively
spliced variant encodes variant missing 59 amino acid (resi-
dues 397–456). This variant is catalytically inactive and its
biological relevance is not clear yet (Kmoch et al 2000).
To date, over 50 different ADSL mutations have been
identified in individuals with ADSL deficiency. A majority
of the identified mutations represent missense mutations pre-
senting in heterozygosis and producing an altered ADSL
protein (Human Gene Mutation Database). A mutation of a
regulatory region of the ADSL gene (in a nuclear respiratory
factor 2 binding site in the promoter region) has also been
identified in five patients (Marie et al 2002) as well as a
mutation creating a new splice site and resulting in a 39 base
pair deletion (Kohler et al 1999; Marie et al 1999). Mutation
c.774_778insG results in the introduction of an early stop
codon in position 284 of the protein (Chen et al 2010) and
mutation c.889_891dupAAT predicted a duplication of the
Asn297 residue at the active site of the enzyme (van
Werkhoven et al 2013). Two-thirds of the diagnosed patients
are compound heterozygotes and most mutations are private.
The most commonmutation, accounting for about one third of
the patients’ alleles investigated, is a missense mutation
R426H mutation.
Purinosome
Recently, the existence of the purinosome has been de-
scribed (An et al 2008). The purinosome is a multienzyme
complex of the de novo purine synthesis (DNPS) enzymes
Fig. 2 a-c. Axial and sagittal T2-weighted and T1-weighted cranial
magnetic resonance imaging of a patient with type I ADSL deficiency:
arrows indicate myelination of the posterior limbs of the internal capsules,
enlarged subarachnoid space in the frontal regions, widened lateral
ventricles (especially enlargement of the body and occipital horns), wide
Sylvian fissures with hypoplasia operculum, thin corpus callosum and
lack of myelination of the white matter volume
Fig. 3 a-b. Axial T2-weighted
and T1-weighted cranial magnetic
resonance of a patient with type I
ADSL deficiency: arrows indicate
symmetrical widening of the
lateral ventricles, enlarged sulci of
the brain cortex gyri, especially in
the parieto-occipital lobes
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(including ADSL) that cells transiently assemble in their
cytosol upon depletion or increased demand of purines.
The process of purinosome formation was first demon-
strated and studied in HeLa and human C3A liver carci-
noma cells transiently expressing recombinant fluores-
cently labeled DNPS proteins (An et al 2008). Then the
existence of purinosome was proved in vivo conditions in
cancer and normal non-transfected cells (Baresova et al
2012).
The later studies showed that the first three enzymes in
the pathway form a core of the purinosome (Deng et al
2012) and are substrates for protein kinase CK2, which
suggests dynamic regulation by post-translational modifi-
cations (An et al 2010a, b). The assembly and disassem-
bly of purinosomes are correlated with the rate of DNPS
and for its formation the intact network of microtubules is
needed (An et al 2010a, b). Also methenyltetrahydrofolate
synthetase association with the purinosome in mammalian
cells was studied and dependence of this process on
methenyltetrahydrofolate synthetase stimulation was ob-
served (Field et al 2011).
The study of purinosome formation in skin fibroblasts of
the patients with ADSL deficiency showed that significant
differences of purinosome assembly exists among individual
cases with ADSL deficiency and that the ability to form
purinosomes inversely correlates with the severity of the
phenotype (Baresova et al 2012). This finding corroborates
the hypothesis that the phenotypic severity of ADSL deficien-
cy is mainly determined by structural stability and residual
catalytic capacity of the corresponding mutant ADSL protein
complex, as this is a prerequisite for the formation and stabil-
ity of the purinosome and at least partial channeling of
SAICAR through the DNPS pathway (Zikanova et al 2010;
Vliet et al 2011).
Population variability of ADSL
Population sequencing (Exome sequence project) so far re-
vealed 42 non-synonymous variants in ADSL gene, 25 is
classified as probably damaging, four possibly damaging
and 13 benign. Out of these variants five were already iden-
tified in patients, the most common mutation in ADSL pa-
tients R426H was not present. The probability of heterozy-
gotes for a pathogenic ADSL mutation is about 1:10000.
Genotype-phenotype correlations and structural stability
Current findings indicate that the severity of the clinical
symptoms correlate with the residual enzymatic activity
and stability of the recombinant mutant enzyme (Kmoch
et al 2000; Ariyananda Lde et al 2009; Zikanova et al
2010; Ray et al 2013). In other words, the phenotypic
severity in ADSL deficiency probably reflects the degree
of structural stability and residual enzyme activity of the
corresponding ADSL enzyme complex. This can be doc-
umented best by the biochemical properties of the recom-
binant mutant proteins associated with the neonatal fatal
phenotype. These proteins display the lowest residual
Fig. 4 Photos of patients with
type II adenylosuccinate lyase
deficiency
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activity and significant thermal instability and the muta-
tions mostly affect residues forming the catalytic sites or
residues involved in substrate channeling. Recombinant
mutant proteins associated with type II disease displayed
mostly normal enzymatic activity; the proteins are stable,
and the mutations seemed to be structurally benign based
on in silico analysis of the ADSL structure. The patho-
genic effects of these biochemically benign and structur-
ally stable mutations, therefore, are probably not related
to their intrinsic structural and/or catalytic properties but
rather to abnormalities that may manifest only under
in vivo conditions inside eukaryotic cells. Such mutations
may affect protein folding, purinosome formation
(Baresova et al 2012), slow down enzyme complex for-
mation and/or lead to accelerated degradation. These
mechanisms may decrease the amount of otherwise nor-
mally functioning enzyme complex and lead to a much
milder enzyme deficiency (Zikanova et al 2010).
In all cases studied so far, the combination of mutations
produce ADSL enzymes that retain some residual enzyme
activity (Van den Bergh et al 1993a, b; Van den Bergh et al
1993a, b); complete lack of ADSL activity in humans is
probably lethal.
Pathophysiologic mechanisms
Hypotheses regarding the pathogenesis include toxicity
of high levels of SAICAR, AMPS, or their metabolites,
deficiency of the de novo purine biosynthetic pathway,
or lack of a completely functional purine cycle in mus-
cle and brain.
Toxic effects of intermediates
The main pathogenic effect has been attributed to the toxic
effects of accumulating succinylpurines (Stone et al 1998).
Although the absolute S-Ado and SAICAr concentrations in
body fluids do not correlate with the severity of the phenotype,
it has been found that different values for the ratio between S-
Ado and SAICAr concentrations in cerebrospinal fluid (S-
Ado/SAICAr ratio) correspond with the three main phenotyp-
ic groups (Van den Bergh et al 1993a, b; Mouchegh et al
2007):
i) In patients with the neonatal fatal form, the S-Ado/
SAICAr ratio is less than 1.
ii) In patients with the severe childhood form, the S-Ado/
SAICAr ratio is close to 1.
iii) In patients with the moderate or mild form, the S-Ado/
SAICAr ratio is more than 2.
The observation of less severe intellectual impairment
in patients with similar SAICAr levels but S-Ado/
SAICA-r ratios above 2, suggests that SAICA-r is the
offending/neurotoxic compound, and that S-Ado may be
protective of SAICAr’s effects. The finding that infusion
of SAICAr to rats induces neuronal damage in specific
regions of the hippocampus is consistent with this hy-
pothesis (Stone et al 1998). To date, however, all at-
tempts to demonstrate evidence of neurotoxicity of the
succinylpurines in humans have failed.
Biochemical and structural analysis of mutant ADSL
enzyme complexes have shown that different S-Ado/
SAICAr ratios do not result from disproportionate
SAMP and SAICAR enzyme activities. Almost all of
the mutant protein complexes, if active, displayed a
proportional decrease in activity toward both of the
enzyme substrates.
It seems that the ratio of the accumulating S-Ado and
SAICAr in body fluids is not predictive of phenotype severity;
rather, it may be secondary to the degree of the patient’s
development (i.e., to the age of the patient at the time of a
sample collection) (Zikanova et al 2010).
Deficiency of Purine Nucleotides
Deficient synthesis of purine nucleotides caused by
ADSL deficiency has been hypothesized to have detri-
mental effects during embryo development, primarily
depending on de novo purine synthesis. However, nor-
mal levels of purine nucleotides were measured in var-
ious patients’ tissues (Van den Berghe and Jaeken
1986). This suggests that ADSL activity, although deep-
ly reduced, may not be limiting for the de novo syn-
thesis or that salvage pathway involving the enzymes
hypoxanthine-guanine phosphoribosyltransferase, ade-
nine phosphoribosyltransferase and adenosine kinase
may compensate for the deficiency (Jaeken and Van
den Berghe 1984; Jaeken et al 1988). Nevertheless, a
deficiency of purine nucleotides could occur in some
hitherto unidentified cell types with profound deficiency
of adenylosuccinate lyase and low activity of the sal-
vage pathway. Little is known about the actual purine
levels in the living brain and about the regulation of
purine synthesis during embryogenesis, which might be
affected by deficits in purine metabolism.
Impairment of energy metabolism
ADSL also participates in the purine nucleotide cycle along
with AMP deaminase and adenylosuccinate synthetase, and
the impairment of this cycle in ADSL deficiency has also been
suggested to cause the disorder. Purine nucleotide cycle con-
trols the level of fumarate, a Krebs cycle intermediate, and of
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AMP, particularly maintaining the ATP/AMP ratio in muscles
(Van den Berghe et al 1992).
Diagnosis, diagnostic criteria, diagnostic methods
Diagnosis requires the following:
– demonstration of succinylaminoimidazolecarboxamide
riboside (SAICAr) and succinyladenosine (S-Ado) in
extracellular fluids such as plasma, cerebrospinal fluid
and/or urine using HPLC with UV detection or HPLC-
MS,
– mutation analysis — genomic and/or cDNA sequencing
of ADSL gene and characterization of mutant proteins.
Diagnosis is supported by the following:
– evidence of clinical phenotype,
– demonstration of SAICAr and S-Ado in extracellular
fluids such as urine, cerebrospinal fluid and/or plasma
using simple screening tests such as Bratton-Marshall or
thin-layer chromatography,
– the analysis of ADSL enzyme activity in cultured skin
fibroblasts at an accredited laboratory to demonstrate
large decrease of ADSL activity. Although ADSL en-
zyme activity levels may be different between testing
laboratories, ADSL activity in diagnosed ADSL patients
is generally between 2-20 % of the lower limit of normal
ADSL activity (Salerno et al 1995). Enzyme assay in
lysates is not completely reliable due to tissue heteroge-
neity of ADSL defect (Mouchegh et al 2007).
Biochemical diagnostic methods
All standard laboratory investigations are normal: no signs of
hypoglycemia, hypomagnesaemia or hypocalcaemia, and the
laboratory metabolic investigations such as liver function
tests, plasma lactate and pyruvate, ceruloplasmin, thyroid-
stimulating hormone, amino acids, and organic acids are
normal.
The deficiency of ADSL activity results in accumulation of
SAICAR and SAMP in the cells and the presence of enor-
mously elevated concentrations of their dephosphorylated
forms, SAICAr and S-Ado in extracellular fluids — urine
and CSF, and to a lesser extent also in plasma. SAICAr and
SAdo are present in low micromolar concentrations in body
fluids of controls (Sebesta et al 1997; Krijt et al 1999). Several
methods have been described for selective screening of sub-
jects with ADSL deficiency that allow identification of either
two or one of the relevant compounds in body fluids. The
most commonly used include Bratton-Marshall test, thin-layer
chromatography (TLC) for identification of SAICAr
(Wadman, de Bree et al 1986), S-Ado (Maddocks and Reed
1989) and both nucleosides (Jaeken and van den Berghe
1989), isolation of SAICA riboside and S-Ado with a cation
exchange resin and determination of A270/A250 ratio (UV
absorbance of the ammonia eluate at 270 and 250 nm)
(Domkin et al 1995), capillary electrophoresis (Gross et al
1995; Hornik et al 2007), and high resolution proton magnetic
resonance spectroscopy (Wevers et al 1995; Henneke et al
2010). Bratton-Marshall test and TLC with Pauly reagent
detects the presence of excessive urinary SAICA riboside
(Laikind et al 1986), but may be false negative due to
bacteria-mediated deribosylation of SAICAr and SAdo in
urine (Krijt et al 2013) or SAICAr instability. The advantage
of the Bratton-Marshall test is its simplicity of equipment and
procedure, and the speed of test (Laikind et al 1986). HPLC-
DAD, LC-MS/MS or other screening methods allowing si-
multaneous detection of SAICA-riboside ade and SAdo
should be preferentially used for the diagnosis of ADSL
deficiency. HPLC-DAD method employs resolution of
SAdo and SAICAr from serum, urine, and CSF by reverse-
phase high-pressure liquid chromatography (RP-HPLC) with
detection by UV spectroscopy (Jaeken and Van den Berghe
1984; de Bree et al 1986; Jaeken et al 1988). The compounds
are identified by spectral analyses and comparison to available
standards. This method gives accurate results and has the
advantage of quantifying the excretion of a large number of
compounds. However, it requires expensive, specialized
equipment and is usually employed as a second step to further
identify the metabolite accumulating in any sample that gives
a positive Bratton-Marshall or TLC test. Recently, high-
throughput urine screening techniques for ADSL deficiency
have been developed using HPLC combined with
electrospray ionization (ESI) tandem mass spectrometry
(MS/MS) (Ito et al 2000; Hartmann et al 2006; van van
Werkhoven et al 2013). These methods allow rapid and spe-
cific screening for disorders of purine and pyrimidine metab-
olism with use of liquid urine samples or urine-soaked filter
paper strips.
Differential diagnoses
Differential diagnoses within ADSL deficiency include:
Neurological disorders with intractable seizures and
encephalopathy
Other inborn errors of purine and pyrimidine (P/P) metab-
olism with neurological manifestations
The wide clinical spectrum of the disease accounts for
possible difficulties in differential diagnosis with neurological
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disorders especially those with intractable seizures and
encephalopathy.
In the neonatal period, differential diagnosis should firstly
be made with five treatable disorders that can present predom-
inantly with intractable seizures: pyridoxine responsive sei-
zures, pyridox(amine)-5'-phosphate oxidase deficiency,
folinic acid-responsive seizures, 3-phosphoglycerate dehydro-
genase deficiency, and hyperinsulinemic hypoglycemia
(Saudubray et al 2006). Biotin-responsive holocarboxylase
synthetase deficiency can also rarely present with neonatal
seizures. In the first months of life, biotin-responsive biotini-
dase deficiency and GLUT1 deficiency, treatable by a
hyperketotic diet, can also present with intractable seizures.
Other, nontreatable inborn errors of metabolism can present in
the neonatal period with severe epilepsy: nonketotic
hyperglycinemia, D-2-hydroxyglutaric aciduria, mitochondri-
al glutamate transporter defect, peroxisomal biogenesis de-
fects, respiratory chain disorders, sulfite oxidase deficiency,
and Menkes disease. In infancy, the association of seizures
and autistic features should prompt differential diagnosis with
Angelman syndrome.
Other inborn errors of purine and pyrimidine metabolism
may present early in life with similar symptoms as ADSL
deficiency. Selective screening for purines and pyrimidines is
very valuable especially in children with nonspecific neuro-
logical symptoms.
Prenatal diagnosis, selective screening and genetic
counseling
Prenatal diagnosis is limited to families having a previous
child with ADSL deficiency and is based on mutational anal-
ysis for at-risk fetuses. Diagnostic testing may be conducted
for prenatal diagnosis on viable fetal cells from chorionic villi,
cultured amniotic fluid cells or in the newborn dried blood
spots (Marie et al 2000).
Selective screening for ADSL deficiency
The wide clinical spectrum of the disease accounts for possi-
ble difficulties in differential diagnosis with neurological dis-
orders especially those with intractable seizures and encepha-
lopathy. For this reason, it is important to develop protocols
for ADSL suspects and diagnosis to avoid useless investiga-
tions and treatments. The marked clinical heterogeneity jus-
tifies systemic screening for the disorder in patients with:
– newborns and infants with hypotonia and acquired
microcephaly,
– unexplained psychomotor retardation,
– unexplained developmental delay,
– unexplained seizures especially intractable,
– MRI findings such as atrophy of the cerebral cortex,
corpus callosum, cerebellar vermis, lack of myelination,
delayed myelination, anomalies of the white matter.
Specialties involved
Greater awareness of adenylosuccinate lyase deficiency
amongst pediatricians, neonatologists, pediatric neurologists
but also radiologists is the key to identifying the disorder in
the early stage. Because the majority of newborns with neo-
natal as well as type I of ADSL deficiency have microcephaly,
general pediatricians and neonatologists should exclude
ADSL in newborns and infants with a small head circumfer-
ence. General and emergency care pediatricians must consider
ADSL deficiency in parallel with status epilepticus. Pediatric
neurologists have an important role to play in bringing this
disorder to the attention of the broader pediatric community
and instructing them as to the key diagnostic clues. The
finding of atrophy of the cerebral cortex, corpus callosum,
cerebellar vermis, lack of/or delayed myelination, anomalies
of the white matter or lissencephaly on MRI examination
should alert neonatologists and radiologists to the possibility
of ADSL deficiency.
With such an approach, more patients may benefit from
early diagnosis.
Genetic counseling
When the prospects for treatment or disease-altering manage-
ment are not prominent, patients and family members will
benefit from definitive diagnosis. Diagnosis helps the patient
and family members gain access to appropriate organizations
that provide emotional support as well as practical advice and
assistance in dealing with the life changes that arise as a result
of disability. Accurate diagnosis is vital so that families can
receive genetic counseling about risk recurrence and the pos-
sibility of a- or pre-symptomatic affected relatives.
Therapeutic approaches
D-ribose and uridine administration
Despite the increasing number of ADSL-deficient patients re-
ported, there are only a few communications of therapeutic
considerations and efforts. Among them only two showed some
beneficial effects (D-ribose and uridine administration) (Salerno
et al 1998; Salerno et al 2000). D-ribose administration, which
increases the provision of phosporibosylpyrophosphate (PRPP)
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and stimulates de novo purine synthesis, has been applied in a
few ADSL patients. Salerno et al published promising results in
motor coordination and seizure control in a 13-year-old female
after several months of D-ribose therapy (Salerno et al 1998).
These results, however, have not been confirmed in further
studies (Jurecka et al 2008a, b; Perez-Duenas et al 2011).
S-adenosyl-l-methionine
Recently Werkhoven et al evaluated S-adenosyl-l-methionine
(SAMe) as a potential treatment for ADSL deficiency (van
Werkhoven et al 2013). After 9 months of SAMe treatment,
there was no clear response evidenced in urine metabolite
levels or clinical parameters.
Epilepsy treatment
The aim of treating epilepsy is to control or at least decrease
seizure frequency with minimal side effects. Treatment with
anticonvulsive drugs (e.g., valproic acid, phenobarbital, car-
bamazepine, topiramate, levetiracetam, phenitoin, clobazam)
depends on the type of seizures. Patients with ADSL deficien-
cy often require polypharmacy with the use of two or more
anticonvulsants. Drug resistance is common.
Ketogenic diet
Recently there have been reports about positive use of a
ketogenic diet for treatment of refractory epilepsy (Lefevre
and Aronson 2000; Jurecka et al 2012a, b). Physiological
consequences of a ketogenic diet are similar to fasting and
include hypoglycemia and increased levels of ketone bodies
and fatty acids. Various mechanisms have been hypothesized
for the anticonvulsant effect of the ketogenic diet in ADSL
patient (Jurecka et al 2012a, b). Some of these hypotheses
focus on ketone bodies as crucial mediators of the beneficial
effects of the ketogenic diet. Acetone shows the best anticon-
vulsant effects both in vivo and in vitro models (Masino and
Geiger 2008). As a result of the diet, more glutamate becomes
accessible to the glutamate decarboxylase reaction to yield
gamma-aminobutyric acid (GABA), the major inhibitory neu-
rotransmitter and an important antiseizure agent. In addition,
the ketogenic diet appears to favor the synthesis of glutamine,
an essential precursor to GABA (Yudkoff et al 2007). Both
hypoglycemia and decreased pH are physiological changes
that have been shown to increase adenosine and ATP levels. A
purinenergic signaling hypothesis assumes neuroprotective
and antiseizure actions of a ketogenic diet. Whilst on a keto-
genic diet, increased mitochondrial biogenesis, brain energet-
ics and brain ATP are observed.
A ketogenic diet could be considered a valid therapeutic
option in patients with intractable seizures in a course of
ADSL deficiency, however due to the possibility of side
effects that may present during the diet, patients require a
thorough and systematic examinations, including biochemical
parameters of blood (Jurecka et al 2012a, b).
Prognosis
Lifespan in patients with adenylosuccinate lyase deficiency is
variable: neonatal forms may lead to early death, whereas
onset in early childhood usually entails stable evolution.
There are important issues to be considered when counseling
families regarding prognosis and prenatal diagnosis. One is
uncertainty regarding the long-term outcome in patients with
milder phenotypes. Another complicating issue in genetic
counseling is the unpredictability of phenotype in individuals
with the same ADSL phenotype. The clinical heterogeneity in
ADSL phenotype is not well understood.
Concluding remarks
Adenylosuccinate lyase deficiency is a progressive disease
with central nervous system involvement. As our knowledge
about the natural history of ADSL deficiency increases, it
becomes evident that the disease manifests symptoms along
a continuum ranging from severe to mild. Clinical heteroge-
neity is especially prominent in the less severe end of the
spectrum and some attenuated patients may present no obvi-
ous signs of disease progression and degradation. Case
reports/series are therefore particularly important to expand
our knowledge and understanding of the disease. The
pathomechanism of the disease still remains unclear and re-
quires further research. To date, there is no specific and
effective therapy for adenylosuccinase deficiency despite a
few attempts that have been made. The purinosome may also
represent a new pharmacological opportunity for therapeutic
intervention.
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